RU58841 is discussed as a hair loss treatment, with users considering lower doses like 2.5% to reduce costs. Some users suggest that if already blocking DHT, lower doses might still be effective unless there's high sensitivity to DHT.
The conversation discusses the importance of scalp biopsies for diagnosing hair loss conditions like DUPA and Retrograde, which may not be just AGA. It emphasizes that treatments like finasteride and dutasteride may not work if the condition is autoimmune.
A user experienced hair thinning and increased shedding after starting a high-dose B-complex supplement while using Minoxidil and RU58841. They are seeking advice on whether others have had similar issues with high doses of Vitamin B3 and B5.
The user was diagnosed with DUPA and initially treated with finasteride, then switched to dutasteride which worsened their hair loss. They are now returning to finasteride and adding treatments including oral minoxidil, Proscar, Viviscal, pumpkin seed oil, LLLT, and Nizoral shampoo, hoping for hair regrowth.
Procapil is marketed as a natural hair loss treatment but lacks strong evidence and is industry-biased. Minoxidil and Finasteride are the only FDA-approved treatments for androgenetic alopecia.
Doctors are testing verteporfin topically for healing and potential regeneration after transplants. The user is asking how it is formulated for topical use, such as if it's mixed with a carrier gel.
The user experienced worsening hair density after using finasteride, dutasteride, and RU58841, suspecting RU58841 might be the cause. They are considering stopping RU58841 after a scalp biopsy, while others share mixed experiences with RU58841's effectiveness.
The user is experiencing hair loss despite using Dutasteride and plans to try RU58841, considering adding Oral Minoxidil. They express frustration with diffuse thinning and seek advice on managing hair loss.
PP405 is considered a promising hair loss treatment, potentially replacing minoxidil but not finasteride. Users are hopeful for future treatments like GT20029 and VDPHL01, while remaining cautious about effectiveness and side effects.
A new drug, PP405, is being discussed as a potential cure for baldness, with hopes it could be more effective than Minoxidil and Finasteride. Users are skeptical about its effectiveness and the need for lifelong use.
The conversation discusses creating a foam version of RU58841 for easier application on thick hair, comparing it to minoxidil foam. The user currently uses dutasteride, minoxidil, and needling for hair loss treatment.
The conversation discusses the effectiveness of reducing DHT for hair loss treatment and explores alternative approaches like reducing androgen receptor sensitivity. Specific treatments mentioned include finasteride, dutasteride, pyrilutamide (KX-826), GT20029, and RU58841.
The conversation discusses a patent filed by Shiseido for cloning Dermal Papilla (DP) cells to treat hair loss. The method involves using viral vectors to maintain the cells' growth-inducing properties, differing from Replicel's approach with Dermal Sheath Cup (DSC) cells.
Clascoterone 5% and PP405 are being discussed as potential future treatments for hair loss, with clascoterone nearing phase three completion and PP405 possibly taking a cosmetic route to market. Current treatments like minoxidil, finasteride, and RU58841 are mentioned as effective in slowing hair loss, but a complete cure remains elusive.
A user's experience with hair loss and scalp inflammation, which was alleviated by using RU58841 along with finasteride and dutasteride. A theory of inflammation possibly being a cause of hairloss is also discussed.
The conversation discusses alternatives to Dr. B's hair loss treatments, specifically mentioning Minoxidil, Finasteride, and RU58841. A user notes a price discrepancy on a website.
A Silicon Valley-backed company aims to cure hair loss. Exciting advancements include mRNA therapies, gene editing, hair cloning, AR degraders, anti-androgens, cell-based rejuvenation, and AI-based drug discovery, with hopes for FDA approval of GT20029 within 10 years.
User's 2-month progress with hair loss treatment includes Ket 3x a week, Min 2x a day, Dut 0.5 every other day, Vit D 125mcg daily, and PRP once a month. Users discuss treatment effectiveness, side effects, and alternative solutions.
A 24-year-old experiencing severe hair thinning has been using minoxidil for 2 years but is still shedding hair. A doctor recommended plasma treatment over a DHT blocker for better and healthier results.
The conversation discusses CRISPR-on & CRISPR-off as a potential cure for baldness, contrasting it with hair cloning and other treatments like Minoxidil, finasteride, and RU58841. It also mentions the potential of mRNA for gene expression control and the prioritization of gene editing for severe genetic conditions.
Epristeride is a selective 5 alpha reductase type 2 inhibitor that may reduce scalp DHT similarly to finasteride, with potentially fewer side effects. It is suggested that combining epristeride with finasteride or dutasteride could enhance hair loss treatment effectiveness.
A 24-year-old with hair thinning is using a regimen including dutasteride, RU58841, HGH, GHK-cu, and other compounds to protect and regrow hair. They are also incorporating a mild cutting cycle with testosterone propionate, anavar, and tirzepatide.
The user experienced a sudden decrease in hair density after starting alfatradiol while already using finasteride. Another user mentioned that initial shedding can occur with hair loss treatments, but it may not last long.
Ecklonia cava is suggested as an alternative to finasteride and dutasteride for hair growth, potentially offering benefits without their side effects. It is promoted for anti-aging, mood enhancement, and cognitive support.
The conversation discusses using finasteride or dutasteride to reduce DHT, CosmeRNA to target androgen receptors, and Minoxidil as a vasodilator for hair growth. The regimen aims to maintain hair by addressing DHT-AR ratio and continuous Minoxidil use.
A user is concerned that prolonged use of valisone (betamethasone) and clotrimazole solution for scalp dermatitis may be causing hair thinning and loss. They noticed thinning in the area where the solution was applied.
The conversation is about a user experiencing accelerated hair loss after starting vitamin D3 supplements, suspecting a link between the supplement and increased DHT levels. The user decides to stop taking the supplements, preferring natural sources of vitamin D.
Minoxidil, finasteride, and RU58841 are discussed as treatments for reducing hair thinning. The conversation focuses on the effectiveness of these ingredients in addressing hair loss.
PP405 shows initial promise for treating androgenetic alopecia, with safety confirmed in early trials, but skepticism remains due to limited data. Further trials are needed to determine its true efficacy and potential market impact.